Energy Deficiency, ATG4B Nuclear Translocation, and DNA Repair in Acute Myeloid Leukemia

Study Background and Research Question

Cellular energy metabolism and genomic stability are both crucial for maintaining cellular homeostasis. Their independent roles in health and disease are well-recognized, but the precise molecular crosstalk between these domains, especially in oncogenic contexts such as acute myeloid leukemia (AML), remains insufficiently characterized. It is well established that DNA repair mechanisms are ATP-intensive and that metabolic disruptions can generate reactive oxygen species, compounding DNA damage. Yet, the direct molecular mechanisms by which energy deficiency impairs DNA repair and accelerates the malignant evolution of leukemia have been largely speculative until now.

Key Innovation from the Reference Study

The reference paper (Wang et al., 2025) provides a definitive mechanistic link connecting cellular energy deficiency to defective DNA repair in AML. The authors identify that under energy-deprived conditions, the autophagy regulator ATG4B translocates from the cytoplasm to the nucleus, where it physically interacts with PRMT1, a protein arginine methyltransferase critical for DNA repair. This nuclear ATG4B inhibits the PRMT1-dependent methylation of MRE11, a core component of the MRN complex essential for DNA double-strand break repair. The disruption of this methylation event leads to compromised DNA repair capacity and increased genomic instability, thereby promoting leukemia progression. This insight fills a major gap in understanding how metabolic stress can directly undermine genomic maintenance in cancer cells.

Methods and Experimental Design Insights

The study employs a multifaceted experimental design, integrating cellular, molecular, and in vivo approaches to dissect the mechanistic pathway:

• Energy deficiency was induced in cultured leukemia cells using metabolic inhibitors and nutrient deprivation protocols.
• ATG4B subcellular localization was visualized using immunofluorescence and subcellular fractionation, demonstrating its dynamic nuclear translocation under energy stress.
• Protein-protein interactions between ATG4B and PRMT1 were confirmed by co-immunoprecipitation and proximity ligation assays.
• Functional consequences on DNA repair were assessed through comet assays, γ-H2AX foci quantification, and direct analysis of MRE11 methylation status.
• The biological impact was validated in both patient-derived AML samples and in mouse models bearing MLLT3-KMT2A-driven AML, providing translational relevance.
• Pharmacological and genetic inhibition of ATG4B was used to probe the reversibility of DNA repair defects and effects on disease progression.

Protocol Parameters

• Energy deficiency induction: Glucose deprivation or treatment with metabolic inhibitors for 12–24 hours in AML cell lines to mimic cellular energy stress.
• ATG4B inhibition: siRNA-mediated knockdown or small-molecule inhibitors applied for 48–72 hours in vitro; for in vivo studies, dosing regimens were tailored to mouse models bearing MLLT3-KMT2A–induced AML.
• DNA repair assessment: Comet assays and γ-H2AX immunofluorescence performed post-energy stress and/or ATG4B inhibition to quantify DNA breaks and repair kinetics.
• Protein interaction analysis: Co-immunoprecipitation performed on nuclear extracts to detect ATG4B–PRMT1 complexes, followed by immunoblotting for methylated MRE11.
• Animal models: Patient-derived xenograft mice and genetically defined AML models monitored for survival, mutation burden, and leukemia progression after modulation of ATG4B activity.

Core Findings and Why They Matter

Key results from the reference investigation include:

• ATG4B nuclear translocation is energy-dependent: Under metabolic stress, ATG4B consistently accumulates in the nucleus.
• ATG4B inhibits PRMT1-mediated MRE11 methylation: The direct interaction reduces the methylation-dependent activation of the DNA repair factor MRE11, leading to impaired homologous recombination repair.
• Genomic instability and AML progression: Patient-derived and mouse AML cells under energy deficiency exhibit higher DNA damage and increased mutational load, which is exacerbated by ATG4B activity.
• Therapeutic angle: Inhibition of ATG4B restores DNA repair capacity, reduces proliferation, and extends survival in AML models, nominating ATG4B as a potential therapeutic target to counteract metabolic-genomic vulnerabilities in leukemia.

These findings clarify the molecular axis by which metabolic stress can directly fuel genetic instability and malignant progression in hematologic cancers. They also suggest that interventions targeting the ATG4B–PRMT1–MRE11 axis may offer new avenues for therapeutic development, particularly in settings of metabolic compromise.

Comparison with Existing Internal Articles

Previous internal reviews, such as "Energy Deficiency, ATG4B Nuclear Translocation, and DNA Repair in AML", have broadly summarized the relationship between energy deprivation and DNA repair impairment, highlighting ATG4B's role. The present reference study distinguishes itself by providing direct molecular evidence for the ATG4B–PRMT1–MRE11 pathway, supported by rigorous in vivo validation. In contrast, articles such as "Tioconazole in Antifungal Research: Protocols, Use-Cases, and Optimization" focus primarily on antifungal medication workflows, but similarly emphasize the importance of experimentally validated molecular mechanisms in drug development. While mechanistically distinct, both research lines stress the value of targeting metabolic and repair pathways for disease modulation and therapeutic advancement.

Limitations and Transferability

Despite its comprehensive design, the study is limited by the cancer type focus (AML), and the findings may not be directly generalizable to other malignancies or normal tissues. The reliance on patient-derived xenografts and mouse models strengthens translational relevance but cannot fully recapitulate the complexity of human disease. Interactions between ATG4B and PRMT1 may also have context-dependent effects in other cellular states. Further research will be required to determine whether similar mechanisms operate in solid tumors or under different metabolic stressors.

Research Support Resources

For researchers investigating metabolic-genomic interactions, robust in vitro and in vivo modeling is essential. Standardized reagents, such as the antifungal medication Tioconazole (SKU B2051), are widely used as controls in studies of fungal cell membrane ergosterol synthesis inhibition and can support the development of fungal infection models and antifungal drug development protocols. According to the product information, Tioconazole is supplied at high purity and is suitable for reproducible in vitro antifungal assays, which may be relevant for laboratories modeling infection-driven metabolic stress as a variable in cancer or DNA repair research. It is recommended to follow validated workflows and consult the latest literature to align experimental design with evolving mechanistic insights.